Douglas A E White1, Erik S Anderson2, Sarah K Pfeil2, Tarak K Trivedi2, Harrison J Alter2. 1. Department of Emergency Medicine, Alameda Health System, Highland Hospital, Oakland, CA. Electronic address: dwhite@alamedahealthsystem.org. 2. Department of Emergency Medicine, Alameda Health System, Highland Hospital, Oakland, CA.
Abstract
STUDY OBJECTIVE: We describe the results of an emergency department (ED) hepatitis C virus testing program that integrated birth cohort screening and screening of patients with a history of injection drug use, as well as physician diagnostic testing, according to national guidelines. METHODS: We conducted a retrospective cohort study using data collected as part of clinical care. The primary outcome was the hepatitis C virus prevalence among tested patients. We evaluated factors associated with testing positive with logistic regression. RESULTS: Of the 26,639 unique adults aged 18 years or older and presenting to the ED during the 6-month study, 2,581 (9.7%) completed hepatitis C virus screening (2,028) or diagnostic testing (553), of whom 267 were antibody positive (10.3% prevalence). Factors associated with testing positive for hepatitis C virus included injection drug use (38.4% prevalence; odds ratio [OR] 10.8; 95% confidence interval [CI] 7.5 to 15.5), homeless (25.5% prevalence; OR 3.1; 95% CI 1.5 to 6.8), diagnostic testing (14.8% prevalence; OR 2.6; 95% CI 1.7 to 3.9), birth cohort (13.7% prevalence; OR 3.6; 95% CI 2.4 to 5.3), and male sex (12.4% prevalence; OR 1.4; 95% CI 1.0 to 2.0). Of the 267 patients testing positive for hepatitis C virus antibody, 137 (51%) had documentation of result disclosure and 180 (67%) had confirmatory ribonucleic acid testing performed, of whom 126 (70%) had a positive result. Follow-up appointments at the hepatitis C virus clinic were arranged for 57 of the 126 (45%) patients with confirmed positive results, of which 30 attended. CONCLUSION: This ED screening and diagnostic testing program found a high prevalence of hepatitis C virus antibody positivity across all groups. Challenges encountered with hepatitis C virus screening included result disclosure, confirmatory testing, and linkage to care. Our results warrant continued efforts to develop and evaluate policies for ED-based hepatitis C virus screening.
STUDY OBJECTIVE: We describe the results of an emergency department (ED) hepatitis C virus testing program that integrated birth cohort screening and screening of patients with a history of injection drug use, as well as physician diagnostic testing, according to national guidelines. METHODS: We conducted a retrospective cohort study using data collected as part of clinical care. The primary outcome was the hepatitis C virus prevalence among tested patients. We evaluated factors associated with testing positive with logistic regression. RESULTS: Of the 26,639 unique adults aged 18 years or older and presenting to the ED during the 6-month study, 2,581 (9.7%) completed hepatitis C virus screening (2,028) or diagnostic testing (553), of whom 267 were antibody positive (10.3% prevalence). Factors associated with testing positive for hepatitis C virus included injection drug use (38.4% prevalence; odds ratio [OR] 10.8; 95% confidence interval [CI] 7.5 to 15.5), homeless (25.5% prevalence; OR 3.1; 95% CI 1.5 to 6.8), diagnostic testing (14.8% prevalence; OR 2.6; 95% CI 1.7 to 3.9), birth cohort (13.7% prevalence; OR 3.6; 95% CI 2.4 to 5.3), and male sex (12.4% prevalence; OR 1.4; 95% CI 1.0 to 2.0). Of the 267 patients testing positive for hepatitis C virus antibody, 137 (51%) had documentation of result disclosure and 180 (67%) had confirmatory ribonucleic acid testing performed, of whom 126 (70%) had a positive result. Follow-up appointments at the hepatitis C virus clinic were arranged for 57 of the 126 (45%) patients with confirmed positive results, of which 30 attended. CONCLUSION: This ED screening and diagnostic testing program found a high prevalence of hepatitis C virus antibody positivity across all groups. Challenges encountered with hepatitis C virus screening included result disclosure, confirmatory testing, and linkage to care. Our results warrant continued efforts to develop and evaluate policies for ED-based hepatitis C virus screening.
Authors: Elissa M Schechter-Perkins; Nancy S Miller; Jon Hall; Joshua J Hartman; David H Dorfman; Chris Andry; Benjamin P Linas Journal: Acad Emerg Med Date: 2018-07-20 Impact factor: 3.451
Authors: Michael S Lyons; Vidhya A Kunnathur; Susan D Rouster; Kimberly W Hart; Matthew I Sperling; Carl J Fichtenbaum; Kenneth E Sherman Journal: Clin Infect Dis Date: 2016-02-21 Impact factor: 9.079
Authors: Eshan U Patel; Oliver Laeyendecker; Yu-Hsiang Hsieh; Richard E Rothman; Gabor D Kelen; Thomas C Quinn Journal: J Clin Virol Date: 2016-05-10 Impact factor: 3.168
Authors: Judith I Tsui; Claire M Miller; John D Scott; Maria A Corcorran; Julia C Dombrowski; Sara N Glick Journal: Drug Alcohol Depend Date: 2018-12-26 Impact factor: 4.492
Authors: Lucia V Torian; Uriel R Felsen; Qiang Xia; Fabienne Laraque; Eric J Rude; Herbert Rose; Adam Cole; Angelica Bocour; Gary J Williams; Robert F Bridgforth; Lisa A Forgione; Howard Doo; Sarah L Braunstein; Demetre C Daskalakis; Barry S Zingman Journal: Am J Public Health Date: 2018-03-22 Impact factor: 9.308
Authors: Alex D Federman; Natalie Kil; Joseph Kannry; Evie Andreopolous; Wilma Toribio; Joanne Lyons; Mark Singer; Anthony Yartel; Bryce D Smith; David B Rein; Katherine Krauskopf Journal: Med Care Date: 2017-06 Impact factor: 2.983
Authors: Joshua A Blackwell; Joel B Rodgers; Ricardo A Franco; Stacey S Cofield; Lauren A Walter; James W Galbraith; Erik P Hess Journal: Am J Emerg Med Date: 2019-11-29 Impact factor: 2.469